Answers are grounded in this paper and cite their sources.
Evaluates payment fees in sub-dollar transactions, suggesting byte-based solutions can reduce costs.
Designing payment infrastructure for sub-dollar transactions requires architectures that minimise value-dependent cost overhead. This study comparatively evaluates fee structures across five payment providers — PayPal, Stripe, Visa, Mastercard, and a blockchain-based Simplified Payment Verification (SPV) implementation — across 55,000 fee evaluations (schedule-computed for legacy providers, transaction-measured for SPV) spanning US$0.01–5.00. A two-part cost model distinguishes fixed-plus-percentage (value-denominated) from byte-denominated fee architectures; hierarchical regression with provider-specific interaction terms quantifies the structural differences (log-level R² = 0.997). The central finding is structural: value-denominated pricing produces hyperbolic cost profiles imposing an uneconomic interval below a provider-specific threshold, whereas byte-denominated pricing yields near-zero absolute fees that vary with transaction byte size (180–1,693 bytes observed) but not with monetary value. In the US$0.01–0.49 band, mean legacy effective fees range from 38.43% (Mastercard) to 237.88% (PayPal); SPV averages 0.06%. Break-even analysis shows legacy providers require US$1.42–14.29 to achieve a 5% effective fee target; SPV achieves this at US$0.002. Sensitivity analysis confirms robustness of the structural ordering to fee multipliers ( 2 × – 10 × ) , legacy discounts (25–50%), EU interchange caps, transaction-size variation, and exchange rate volatility ( ± 90 % ) . The analysis compares direct per-transaction processing fees; excluded cost components are explicitly defined. Four engineering evaluation metrics — fee dispersion, independent verifiability cost, adaptive fee response, and confirmation reliability — provide a reusable assessment framework. The results identify byte-denominated fee design as a structural approach to addressing the micropayment cost barrier.
No takes yet. Share an insight, caveat, or question.
Craig S. Wright (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: